SCHEMBL14713190

SCHEMBL14713190

COC(=O)C(N)Cc1ccc(-c2cnn(C)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.45
MKNK2 Q9HBH9 1/20 0.45
EP300 Q09472 2/20 0.45
CCNC P24863 4/20 0.44
CDK8 P49336 4/20 0.44
AAK1 Q2M2I8 1/20 0.44
CLK1 P49759 2/20 0.43
ACACB O00763 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
PTGS2 P35354 1/20 0.43
PIM1 P11309 1/20 0.43
PIM2 Q9P1W9 1/20 0.43
MAPK8 P45983 1/20 0.42
MME P08473 2/20 0.42
NAMPT P43490 1/20 0.42
PIK3CG P48736 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3628791 1.00 MKNK1 (0.45) MKNK1MKNK2EP300CCNCCDK8
Hydrochloric Acid SCHEMBL540914 0.99 MKNK1 (0.44) MKNK1MKNK2EP300CCNCCDK8
SCHEMBL25754081 0.86 EP300 (0.48) MKNK1MKNK2EP300CCNCCDK8
SCHEMBL25356085 0.85 SLC7A5 (0.50) MKNK1MKNK2EP300CCNCCDK8
SCHEMBL25356081 0.85 SLC7A5 (0.50) MKNK1MKNK2EP300CCNCCDK8
SCHEMBL1124429 0.84 MEN1 (0.42) AAK1ACACBPTGS2ALDH1A1
SCHEMBL21946641 0.84 MEN1 (0.42) AAK1ACACBPTGS2ALDH1A1
Hydrochloric Acid SCHEMBL31752348 0.82 ALDH1A1 (0.42) AAK1ACACBPTGS2ALDH1A1
Hydrochloric Acid SCHEMBL20502547 0.82 ALDH1A1 (0.42) AAK1ACACBPTGS2ALDH1A1
SCHEMBL7262990 0.79 ALDH1A1 (0.44) AAK1ACACBPTGS2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175003-B2 Substituted azoanthracene derivatives and intermediates for preparation thereof VTV THERAPEUTICS LLC (US) 2015-11-03 US disclosed
EP-2413693-B1 SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF VTV THERAPEUTICS LLC (US) 2015-09-09 EP disclosed
US-20150148539-A1 Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof VTV THERAPEUTICS LLC 2015-05-28 US disclosed
US-8987295-B2 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof TRANSTECH PHARMA, LLC (US) 2015-03-24 US disclosed
US-20130096150-A1 Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof TRANSTECH PHARMA, INC. (US) 2013-04-18 US disclosed
US-8383644-B2 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof TRANSTECH PHARMA, INC. (US) 2013-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096150-A1 Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof GLP1R, GIPR, GPR119 MKNK1 1719/4885MKNK2 1865/4885EP300 4295/4885
US-20150148539-A1 Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof GLP1R, GIPR, GPR119 MKNK1 764/4885MKNK2 1318/4885EP300 3829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.